Patent Application
20240100354
This disclosure relates to methods for modulating activity of cells and tissue with materials that are capable of being activated by light, such methods useful for treating diseases. The disclosure also provides devices and systems suitable for use in such methods, particularly devices and systems having oxygen (O2) plasma-treated p-type (boron) silicon.
Extracellular electrical stimulation of excitable cells is the basis for many implantable devices that treat a variety of diseases. While these devices have been efficacious, they are often limited by their bulkiness, mechanical invasiveness, and inability to target single cells. Thus, researchers have looked to optical stimulation techniques, where organic or inorganic photodiode substrates are used for photovoltaic stimulation of cells, including neurons; however, these tools cannot be easily administered in a drug-like fashion. While some photothermally-modulating materials meet these criteria, chronic cellular effects due to heat from such devices are unknown. Optogenetics has been promising for addressing these issues, but fundamentally requires genetic modifications, which can be difficult to implement in vivo. As a result, there is still a need for exploring a non-genetic approach that can be administered in a drug-like fashion.
Silicon (Si) micro- and nano-materials are promising to address these concerns as they have been widely used for many biophysical or biomedical applications due to their highly tunable electrical and chemical properties, ability to absorb a broad range of wavelengths of light, and biocompatibility. Silicon materials, however, have not been widely used largely due to the limited understanding of the physicochemical processes at the material surfaces under physiological conditions.
Therefore, there exists a need for optical methods for modulating cellular behavior using silicon that are not mechanically invasive and do not require genetic manipulation of target cells, yet provide sub-cellular specificity.
The inventors have found that O2 plasma-treated Si-based devices can establish biointerfaces with cells (such as cardiomyocytes) or tissue (such as myocardium). The inventors have also found that the optical cellular-modulation can mimic naturally occurring extracellular signals, i.e., random, fast and multisite input signals, and that such modulation can modulate the activity of a cell or tissue.
Thus, one aspect of the disclosure provides silicon devices. Such devices, in certain embodiments, are O2 plasma-treated p-type (boron type) silicon devices. In certain embodiments, the device of the disclosure is a membrane that includes a flexible substrate on which the device of the disclosure or a plurality of the devices of the disclosure are distributed
Another aspect of the disclosure methods for modulating activity of a cell capable of being activated by light. Such methods include contacting a membrane of the cell with a device of the disclosure as described herein to form a structure-cell membrane interface; and exposing the interface to light under conditions to depolarize the cell membrane thereby increase a threshold for activation of the cell.
Another aspect of the disclosure provides methods of treating a disease in a subject by modulating activation of a cell. Such methods include (i) providing one or more devices of the disclosure as described herein (including membranes); and (ii) exposing the subject to light under conditions sufficient to increase a threshold for activation of the cell and treat the disease.
In certain embodiments, the methods of the disclosure treat a neuronal disease.
In certain other embodiments, the methods of the disclosure treat a cardiovascular disease. For example, in certain aspects of the disclosure, methods of the disclosure optically train myocardium to beat at a target frequency.
Thus, one aspect of the disclosure provides a method for optically training myocardium to beat at a target frequency. This method includes (i) contacting the myocardium with one or more devices of the disclosure as described herein (including membranes); and (ii) operating a light emitter to provide, during a training period of time, a plurality of pulses of light at a stimulation wavelength to the myocardium, wherein the plurality of pulses of light are provided at the target frequency.
The disclosure also provides systems suitable for use in the methods of the disclosure. Thus, in one aspect, the disclosure provides a system for treating a disease in a subject by modulating activation of a cell. Such system includes: (i) one or more devices of the disclosure as described herein or one or more membranes of the disclosure as described herein; (ii) a light emitter configured to emit light at a stimulation wavelength; and (iii) a controller that is operably coupled to the light emitter.
In certain embodiments of this aspect, the disclosure provides a system for optically training myocardium to beat at a target frequency. As provided herein, such system includes: (i) one or more devices of the disclosure as described herein or one or more membranes of the disclosure as described herein; (ii) a light emitter configured to emit light at a stimulation wavelength; and (iii) a controller that is operably coupled to the light emitter.
Other objects, features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the disclosure, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
The accompanying drawings are included to provide a further understanding of the systems and methods of the disclosure, and are incorporated in and constitute a part of this specification. The drawings are not necessarily to scale, and sizes of various elements may be distorted for clarity. The drawings illustrate one or more embodiment(s) of the disclosure and, together with the description, serve to explain the principles and operation of the disclosure.
Before the disclosed methods and materials are described, it is to be understood that the aspects described herein are not limited to specific embodiments, and as such can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and, unless specifically defined herein, is not intended to be limiting.
In view of the present disclosure, the methods and systems described herein can be configured by the person of ordinary skill in the art to meet the desired need. As provided above, inventors have found that O2 plasma-treated Si-based devices can establish biointerfaces with cells (e.g., cardiomyocytes) or tissue (e.g., myocardium). The inventors have also found that the optical cellular-modulation can mimic naturally occurring extracellular signals, i.e., random, fast and multisite input signals, and that such modulation can modulate the activity of a cell or tissue.
As provided above, one aspect of the disclosure methods for modulating activity of a cell capable of being activated by light. Such methods include contacting a membrane of the cell with a device of the disclosure as described herein to form a structure-cell membrane interface; and exposing the interface to light under conditions to depolarize the cell membrane thereby increase a threshold for activation of the cell.
In certain embodiments, the structure-cell interface is a direct interface between the device and the cell membrane (i.e., there are no intervening structures between the silicon device and the cell membrane). In certain embodiments of the methods of the disclosure, the silicon device contacts the membrane without penetrating the membrane. For example, the silicon device may rest on the surface of the cell membrane.
The methods of the disclosure modulate activity of a cell capable of being activated by light. Thus, in certain embodiments, any cell capable of being activated by light may be used in the methods of the disclosure. In some embodiments, the cell is a cardiomyocyte or a neuron. In certain embodiments, the cell is a cardiomyocyte. In certain embodiments, the cell is a neuron.
Another aspect of the disclosure provides methods of treating a disease in a subject by modulating activation of a cell. In certain embodiments of the disclosure, the method is treating a neuronal disease. In certain other embodiments, the methods of the disclosure treat a cardiovascular disease. For example, in certain aspects of the disclosure, methods of the disclosure optically train myocardium to beat at a target frequency. Thus, one aspect of the disclosure provides a method for optically training myocardium to beat at a target frequency. This method includes (i) contacting the myocardium with one or more devices of the disclosure as described herein (including membranes); and (ii) operating a light emitter to provide, during a training period of time, a plurality of pulses of light at a stimulation wavelength to the myocardium, wherein the plurality of pulses of light are provided at the target frequency. In certain embodiments, the device is a membrane that includes a flexible substrate on which the device of the disclosure or a plurality of the devices of the disclosure are distributed and the membrane is configured to be placed in contact with cells of the myocardium such that the devices are in contact with cells of the myocardium. The silicon devices provide, to cells of the myocardium that they are in contact with, excitatory stimulus in response to receiving light at the stimulation wavelength.
The method of the disclosure may be useful as cardiac resynchronization therapy (CRT). In such method, the myocardium is contacted with two or more devices of the disclosure as described herein.
The disclosure also provides systems suitable for use in the methods of the disclosure. As provided above, the disclosure provides a system for treating a disease in a subject by modulating activation of a cell. Such system includes (i) one or more devices of the disclosure as described herein or one or more membranes of the disclosure as described herein; (ii) a light emitter configured to emit light at a stimulation wavelength; and (iii) a controller that is operably coupled to the light emitter. In such systems, the devices provide, to the cell they are in contact with, excitatory stimulus in response to receiving light at the stimulation wavelength. The controller includes one or more processors, wherein the controller is programmed to perform controller operations including: operating the light emitter to provide the light to the cell.
In certain embodiments, the disclosure provides a system for optically training myocardium to beat at a target frequency. As provided herein, such system includes: (i) one or more devices of the disclosure as described herein or one or more membranes of the disclosure as described herein; (ii) a light emitter configured to emit light at a stimulation wavelength; and (iii) a controller that is operably coupled to the light emitter. In certain embodiments, the system is a membrane comprising that includes a flexible substrate on which a device or a plurality of devices of the disclosure as described herein are distributed and the membrane is configured to be placed in contact with a surface of the myocardium such that the devices are in contact with cells of the myocardium. The devices provide, to cells of the myocardium that they are in contact with, excitatory stimulus in response to receiving light at the stimulation wavelength. The controller includes one or more processors and is programmed to perform controller operations including: operating the light emitter to provide, during a training period of time, a plurality of pulses of light to the myocardium, wherein the plurality of pulses of light are provided at the target frequency.
It can be beneficial in a variety of applications to apply the devices (or membranes) as described herein to the stimulation and control of the activity of myocardium (e.g., myocardium of a heart of a person or animal). These devices can be used to efficiently control the pacing of a heart and/or to correct some other deleterious electrical and/or pacing condition of the heart (e.g., bradycardia, tachycardia, ventrical or atrial fibrillation). These devices may additionally or alternatively be used to “retrain” the electrical behavior of the myocardium of the heart, e.g., to train the heart tissue to beat at a more appropriate target rate, to change a pattern of electrical connection or conduction of the heart, or to train the myocardium of the heart in some other manner. The use of the devices of the disclosure may provide a variety of benefits relative to the use of electrodes to pace or otherwise manipulate the heart, e.g., by providing a more energy-efficient interface that has a mechanical compliance that is better matched to the heart tissue.
In order to use the devices described herein to facilitate optical control or manipulation of the electrical and/or physiological properties of myocardium, the silicon devices of the disclosure can be distributed on or within a substrate (e.g., a substrate formed from a polymer). In certain embodiments the substrate is a flexible substrate. Such devices on a substrate are also referred herein as membranes of the disclosure. In certain embodiments, the substrate is a polydimethylsiloxane (PDMS) substrate or poly(methyl methacrylate) (PMMA) substrate. The flexible substrate material can provide a base for the devices, facilitating their organization and implantation within a body (e.g., by contacting with a surface of a heart or some other surface of a myocardial tissue) such that, when the devices receive light at an appropriate wavelength, nearby cardiac cells receive electrical or other stimulus. The substrate, in certain embodiments, can also be a hard, inflexible substrate. One of skill in the art would be able to select suitable inflexible materials that can provide a base for the device.
The silicon devices can be used to provide pulses of optical stimulation in order to cause, manipulate, alter, or otherwise affect the electrical activity of cells of the myocardium. Such pulses of stimulation can provide an entraining stimulus, causing the myocardium to beat or otherwise become electrically active in time with the pulses of stimulation. However, reducing the total energy required to elicit the excitation in the cells of the myocardium for a specific location, pulse width, pulse amplitude, pulse waveform, or other parameters of stimulation is challenging. Yet a reduction of the total energy may be desirable in order to reduce the power requirements of a stimulator device, to reduce phototoxicity in the myocardium, to reduce an amount of localized heating of the myocardium, or to provide some other benefits.
In practice, it can be beneficial to quickly scan the illumination in a point, line, or other shape across the tissue to be stimulated. For example, a spot of illumination can be scanned across the tissue in a plurality of lines or according to some other scan pattern such that the entirety of the tissue surface is briefly illuminated respective periods of time across the scan period. This method was found to provide excellent stimulation of myocardium, especially for “training” the myocardium to pulse at a specified rate, while reducing the overall amount of illumination (e.g., the overall amount of illumination power) required to effect the stimulation. This may be due to the device(s) acting to waveguide and spread the illumination across the surface of the myocardium. Accordingly, each cell of the myocardium may receive a plurality of pulses of illumination during a particular scan, as the point (or line, or other shape) of illumination passes over and/or near the cell.
In certain embodiments, a point, line, or other shape of illumination can be scanned across an area of myocardium by operating a galvanometer to scan the output of a laser or other light-emitting element(s). Such a setup could be implemented in an implanted device setting, e.g., by providing a cowling over the devices, by using mirrors, lenses, optical fiber(s), or other elements to direct the output of the galvanometer to the flexible devices substrate, or in some other manner. Additionally or alternatively, such scanning of illumination across the surface of the myocardium could be accomplished by activating individual light-emitting elements (e.g., LEDs, VCSELs) of an array of light-emitting elements according to a scan pattern. Such light-emitting elements could be disposed on or otherwise directly associated with the flexible devices substrate (e.g., by disposed on the substrate or membrane on which the devices are distributed, by being disposed on a flexible PCB or other substrate that is, in turn, adhered to the membrane substrate). Alternatively, the light-emitting elements could be coupled to respective different locations across the area of the flexible devices substrate, e.g., via respective optical fibers.
In order to stimulate the myocardium to pulse at a target frequency and/or to train the myocardium to pulse at such a target frequency independent of continued stimulation, pulses of illumination may be applied to the myocardium as described above. Each pulse of stimulation could include one or more scans of the illumination across the tissue. For example, a single pulse of illumination could include two or more scans of a point of illumination across the tissue, with the scans repeated at a specified frequency (e.g., 1 kHz). Multiple pulses may be provide during a training period, e.g., at a frequency corresponding to the target myocardial beat frequency (e.g., between 0.5 and 3 Hz). In order to train the myocardium to continue pulsing at the trained frequency, multiple periods of training pulses may be provided, each period of training pulses being separated from the others by a “break period” during which illumination is not provided. The duration of such a break period may be optimized, e.g., to have a two minute duration.
Note that the above methods used the fluorescent and/or electrical detection of cardiomyocyte pulse rate to assess the efficacy of the methods described herein to entrain the electrical activity of myocardium and/or of cardiac cells in culture. However, such detection may also be employed in an implant or other system used to effect training of myocardium in a clinical setting. Such a detected pulse rate may be used to determine that training pulses should be applied to the myocardium, e.g., by determining that the detected pulse rate has deviated from a target frequency by more than a threshold amount. Additionally or alternatively, the detected pulse rate could be used to determine whether sufficient training has been provided, and if not, to provide additional training pulses. For example, a first set of training pulses could be provided and the pulse rate following the training pulses could be detected. If the detected pulse rate deviated from a target by more than a threshold amount, additional training pulses could be provided.
The methods of the disclosure require exposing the interface to light under conditions to depolarize the cell membrane. The depolarization of the cell membrane thereby increases a threshold for activation of the cell. The amount of light needs to be sufficient to accomplish polarization, yet low enough to not harm the cell. Thus, suitable exposing time, wavelength, and power of the light will be selected so to provide the desired activity without the toxicity to the cell. The exposing time may be for a time ranging from 0.5 ms to 15 ms. For example, in certain embodiments, the interface may be exposed for 0.5 ms to 10 ms, or 0.5 ms to 7 ms, or 0.5 ms to 5 ms, or 0.5 ms to 2 ms, or 0.5 ms to 1 ms, or 1 ms to 15 ms, or 1 ms to 10 ms, or 1 ms to 7 ms, or 1 ms to 5 ms, or 1 ms to 2 ms, or 2 ms to 15 ms, or 2 ms to 10 ms, or 2 ms to 7 ms, or 2 ms to 5 ms, or 5 ms to 15 ms, or 5 ms to 10 ms, or 5 ms to 7 ms, or 10 ms to 15 ms. In certain embodiments, the cell is a neuron cell and the exposure time is or 0.5 ms to 7 ms, or 0.5 ms to 5 ms, or 1 ms to 7 ms, or 1 ms to 5 ms. In certain embodiments, the cell is a cardiomyocyte and the exposure time is or 1 ms to 200 ms, or 1 ms to 100 ms, or 10 ms to 100 ms, or 50 ms to 100 ms, or 10 ms to 50 ms.
In certain embodiments, a single pulse is sufficient to modulate activity of a cell. In certain embodiments, two or more pulses are sufficient to modulate activity of a cell. In certain embodiments, 5 or more, or 10 or more, or 25 or more, or 50 or more pulses are sufficient to modulate activity of a cell. In certain embodiments, 1 to 5, or 1 to 10, or 1 to 25, or 1 to 50, or 1 to 100, or 2 to 5, or 2 to 10, or 2 to 25, or 2 to 50, or 2 to 100, or 5 to 10, or 5 to 25, or 5 to 50, or 5 to 100 pulses are sufficient to modulate activity of a cell.
The selection of the wavelength may be determined on the type of silicon device and the amount of light energy required to deactivate the cell without toxicity to the cell. The light may be provided at an excitation wavelength ranging from 400 to 900 nm. For example, in certain embodiments, the light may be provided at an excitation wavelength ranging from 400 to 800 nm, or 400 to 750 nm, or 400 to 600 nm, or 400 to 550 nm, or 500 to 900 nm, or 500 to 800 nm, or 500 to 750 nm, or 500 to 600 nm, or 600 to 900 nm, or 600 to 800 nm, or 600 to 750 nm. The light may be provided at a power in a range of 1 mW to 1 W. For example, in certain embodiments, the light may be provided at a power in a range of 10 mW to 1 W, or 100 mW to 1 W, or 500 mW to 1 W, or 1 mW to 500 mW, or 10 mW to 500 mW, or 100 mW to 500 mW.
As noted above, the methods and systems of the disclosure generally require silicon devices. The devices of the disclosure include any microscale or nanoscale object that can be used in any of the embodiments described herein unless otherwise specified. Devices include nanowires, nanotubes, nanoscaffolds such as mesh and membrane, nanorods, nanowhiskers, and other suitable geometries. “Nanowire” (also “NW,” “SiNW,” or “silicon NW”) as used herein is a nanoscopic wire that is generally a solid wire, and may be elongated in some cases. “Nanotube” is generally nanoscopic wire that is hollow, or that has a hollowed-out core. “Nanoscaffold” is generally a free-standing porous scaffolds such as mesh and membrane. The silicon mesh can be made by photolithography and have a random or regular network of 3D features that can, for example, mimic the size scale and morphology of submicron bioactive extracellular matrices (ECMs). The devices, in some embodiments, may be formed having dimensions of at least about 1 μm, at least about 3 μm, at least about 5 μm, at least about 10 μm, at least about 20 μm, at least about 50 μm, or at least about 100 μm in length, and can be less than about 100 μm, less than about 50 μm, less than about 20 μm, less than about 10 μm, less than about 5 μm, less than about 3 μm, less than about 2 μm, less than about 1 μm, less than about 100 nm, less than about 80 nm, less than about 60 nm, less than about 40 nm, less than about 20 nm, less than about 10 nm, or less than about 5 nm in diameter or thickness (height and width). The devices, in some embodiments, may be formed having dimensions of in a range of about 1 μm to about 5 μm, or range of about 2 μm to about 5 μm, range of about 1 μm to about 3 μm in diameter or thickness (height and width). The devices may have an aspect ratio (length to thickness) of greater than about 2:1, greater than about 3:1, greater than about 4:1, greater than about 5:1, greater than about 10:1, greater than about 25:1, greater than about 50:1, greater than about 75:1, greater than about 100:1, greater than about 150:1, greater than about 250:1, greater than about 500:1, greater than about 750:1, or greater than about 1000:1 or more in some cases.
In some embodiments, at least a portion of a device is doped. As used herein, a “doped” device is a device for which a dopant is incorporated substantially throughout the crystalline lattice of the device, as opposed to a device in which a dopant is only incorporated in particular regions of the crystal lattice at the atomic scale, for example, only on the surface or exterior. “Heavily doped” and “lightly doped” are terms the meanings of which are clearly understood by those of ordinary skill in the art. In some cases, one or more regions may comprise a single monolayer of atoms (“delta-doping”). In certain cases, the region may be less than a single monolayer thick (for example, if some of the atoms within the monolayer are absent). As a specific example, the regions may be arranged in a layered structure within the device, and one or more of the regions may be delta-doped or partially delta-doped.
In certain embodiments, the device contains p-doped regions or is p-doped.
In certain embodiments, the device is undoped.
In certain embodiments, the device is oxygen plasma-treated silicon. In certain embodiments, the device is oxygen plasma-treated p-doped silicon. In certain embodiments, the device is created using wet thermal oxide growth. In certain embodiments, in addition to oxygen-plasma, one or more other gases may be introduced during the plasma treatment. Other gases include, but are not limited to, argon (Ar), chlorine (Cl2), nitrogen (N2), sulfur hexafluoride (SF6), silicon tetrachloride (SiCl4), carbon tetrafluoride (CF4), fluoroform (CHF3), difluoromethane (CH2F2), hexafluoroethane (C2F6), and octafluoropropane (C3F8).
The devices of the disclosure may be plasma treatment for a time ranging from 10 seconds to 60 minutes. For example, in certain embodiments, the plasma treatment is for a time ranging from 1 min to 60 min, e.g., 1 min to 30 min, or 1 min to 20 min, or 1 min to 20 min; or for a time ranging from 5 min to 60 min, e.g., 5 min to 45 min, or 5 min to 30 min, or 5 min to 20 min, or 5 min to 15 min, or 5 min to 10 min; or for a time ranging from 10 min to 60 min, e.g., 10 min to 45 min, or 10 min to 30 min, or 10 min to 20 min.
The devices of the disclosure may be treated with acid, such as hydrofluoric acid (conc. 10-49%) prior to plasma treatment. The acid treatment, in certain embodiments, may be for a time ranging from 1 hours to 72 hours. For example, in certain embodiments, the acid treatment is for a time ranging from 12 hours to 72 hours, e.g., 12 hours to 48 hours, or 12 hours to 24 hours, or 1 hour to 24 hours, 1 hour to 12 hours.
In certain other embodiments, the devices are free or substantially free of gold, silver, or platinum.
The silicon device may be freestanding. As used herein, “freestanding” device means a device free of contact with another device (but not excluding contact of a type that may be desired between individual devices, e.g., as in a crossbar array). For example, a “freestanding” structure may, at some point in its life, not be attached to another structure, for example, with another device, or the free-standing article maybe on a polymer or in solution. This is in contrast to nanotubes produced primarily by laser vaporization techniques that produce materials formed as ropes having diameters of about 2 nm to about 50 nm or more and containing many individual nanotubes (see, for example, Thess, et al., “Crystalline Ropes of Metallic Carbon Nanotubes,” Science, 273:483-486 (1996)). This is also in contrast to conductive portions of structure which differ from surrounding material only by having been altered chemically or physically, in situ, i.e., where a portion of a uniform article is made different from its surroundings by selective doping, etching, etc. A “freestanding” structure is one that can be (but need not be) removed from the location where it is made, as an individual structure, and transported to a different location and combined with different components to make a functional device such as those described herein and those that would be contemplated by those of ordinary skill in the art upon reading this disclosure.
In certain embodiments, the silicon device may be freestanding and suspended in a pharmaceutically acceptable solution, paste, or a hydrogel. The silicon device may be partially suspended or resting on the surface of the pharmaceutically acceptable solution, paste, or a hydrogel. For example, in certain embodiments, one surface of the silicon device is in contact (e.g., covered) with the pharmaceutically acceptable solution, paste, or a hydrogel, while the other surface of the silicon device is uncovered.
The silicon device may be distributed in a flexible substrate comprising one or more of polymers. Distributed silicon device may be partially embedded or on the surface (e.g., bound to the surface) of the flexible substrate. In certain embodiments, partially embedded includes 10%, or 20%, or 30%, or 40%, or 50%, or 60%, or 70%, or even 80% of the total weight of silicon device is embedded into the flexible substrate.
Many suitable flexible substrates are known in the art. In certain embodiments, the flexible substrate is a polymer. In some embodiments, the polymer is selected from a photoresist polymer, a biocompatible polymer, a biodegradable polymer, an extracellular matrix protein, and a combination thereof. In some embodiments, the flexible substrate comprises PDMS. In certain embodiments, the flexible substrate comprises PMMA. In certain embodiments, the flexible substrate comprises PDMS or PMMA, and SU-8 photoresist. In certain embodiments, the flexible substrate is a biodegradable polymer including, but not limited to, poly lactic-co-glycolic acid (PLGA), poly(ethylene glycol) diacrylate (PEGDA), collagen, and gelatin.
In certain embodiments, the flexible substrate has an open porosity of at least about 30%. For example, the flexible substrate has an open porosity of at least about 40%, or 45%, or 50%, or 55%, or even 60%.
Although the Si-based materials are composed primarily of silicon, they can include measurable amounts of other elements. In embodiments, the silicon devices include oxygen. The oxygen may form bonds with silicon such that the oxygen (and some of the silicon) is in the form of an oxide, SiOx.
In certain other embodiments, the devices are free or substantially free of oxygen, and silicon oxide, SiOx.
In an example embodiment, the device comprises a p-type silicon and PDMS as the flexible substrate. These devices may have a geometry, layer thickness, composition, or other configuration specified such that the device provides electrical stimulation when it receives light within a specified range of stimulation wavelengths, e.g., between 900 nanometers and 400 nanometers or between 740 nanometers and 530 nanometers.
The particulars shown herein are by way of example and for purposes of illustrative discussion of certain embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of various embodiments of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for the fundamental understanding of the invention, the description taken with the drawings and/or examples making apparent to those skilled in the art how the several forms of the invention may be embodied in practice. Thus, before the disclosed processes and devices are described, it is to be understood that the aspects described herein are not limited to specific embodiments, apparatus, or configurations, and as such can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and, unless specifically defined herein, is not intended to be limiting.
The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following embodiments and claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.
All methods described herein can be performed in any suitable order of steps unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
Unless the context clearly requires otherwise, throughout the description and the claims, the words ‘comprise’, ‘comprising’, and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to”. Words using the singular or plural number also include the plural and singular number, respectively. Additionally, the words “herein,” “above,” and “below” and words of similar import, when used in this application, shall refer to this application as a whole and not to any particular portions of the application.
As will be understood by one of ordinary skill in the art, each embodiment disclosed herein can comprise, consist essentially of or consist of its particular stated element, step, ingredient or component. As used herein, the transition term “comprise” or “comprises” means includes, but is not limited to, and allows for the inclusion of unspecified elements, steps, ingredients, or components, even in major amounts. The transitional phrase “consisting of” excludes any element, step, ingredient or component not specified. The transition phrase “consisting essentially of” limits the scope of the embodiment to the specified elements, steps, ingredients or components and to those that do not materially affect the embodiment.
All percentages, ratios and proportions herein are by weight, unless otherwise specified.
Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the disclosure are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
Groupings of alternative elements or embodiments of the disclosure are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
Some embodiments of various aspects of the disclosure are described herein, including the best mode known to the inventors for carrying out the methods described herein. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The skilled artisan will employ such variations as appropriate, and as such the methods of the disclosure can be practiced otherwise than specifically described herein. Accordingly, the scope of the disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.
Certain aspects of the disclosure are illustrated further by the following examples, which are not to be construed as limiting the disclosure in scope or spirit to the specific methods and materials described in them.
The general method for preparing the device of the disclosure is illustrated in
Due to the treatment of the device with hydrofluoric acid, pores are formed on the surface and increase the electrochemical surface area of the device. Different duration of treatment creates different surface morphologies on the device and are illustrated in
Different shapes or patterns created in the material can ensure its flexibility around the tissues. As illustrated in
The dependence of the photocurrent generated from the devices are illustrated on the
The device on a substrate (i.e., the membrane) of the disclosure prepared by this method can be readily placed on the heart/sciatic nerve.
The membranes were placed in phosphate buffered saline (PBS) under an upright microscope as illustrated in
As provided in
The membranes of the disclosure were mounted on an isolated heart (using Langendorff apparatus) and stimulated using a collimated 532 nm laser or 477 nm pulses with durations of 1 ms, 10 ms, or 100 ms. The electrocardiogram (ECG) was recorded by electrodes connected to the aorta and left ventricle. Alternatively, the membrane mounted on a PMMA sacrificial layer was treated with acetone to remove the PMMA and released, then moved to PBS and mounted on the heart with no supporting layer.
The results of the optical training are provided in
In contrast to the membranes of the disclosure, the pin membranes with gold decoration did not pace the heart as provided in
The power threshold for optical pacing was measured by gradually increasing the power. This was performed for the 532 laser with two different beam sizes (de-collimated), and with the 477 laser. The lowest power for which overdrive pacing was observed was determined as the pacing threshold. For each condition, the power threshold and the power density (calculated per the beam size) were found. This is illustrated in
The sciatic nerve on an adult rat was exposed as shown in
The sciatic nerve had shown an intensity dependent effect on the outcome of stimulation of an animal limb.
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be incorporated within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated herein by reference for all purposes.
This application claims priority to U.S. application No. 62/915,928, filed Oct. 16, 2019, the disclosure of which is explicitly incorporated by reference herein.
This invention was made with government support under grant number NS101488 awarded by the National Institutes of Health. The government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2020/056106 | 10/16/2020 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 62915928 | Oct 2019 | US |
